Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network (Q33514751)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

13

object named as

Oscar Bertetto

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Alfredo Berruti

2

object named as

Alfredo Berruti

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Luigi Dogliotti

15

object named as

Luigi Dogliotti

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

14

object named as

Mauro Papotti

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

5

object named as

Marco Volante

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

3

object named as

Anna Ferrero

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

Maria P Brizzi

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Enrica Milanesi

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Federico Castiglione

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Nadia Birocco

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sebastiano Bombaci

8

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Davide Perroni

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Benedetta Ferretti

10

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Oscar Alabiso

11

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Libero Ciuffreda

12

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

3 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

388

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

A 5-decade analysis of 13,715 carcinoid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

21 June 2018

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2776604

31 October 2018

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-388

21 January 2018

Antiangiogenesis is produced by nontoxic doses of vinblastine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of combination therapy with interferon-alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19886987

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-388

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33514751&oldid=2195437189"